The impressive €1.35bn ($1.5bn) sum that Forbion raised recently for its two newest funds demonstrates institutional investor belief in the sector, the European venture capital firm said, even while many public and private biotechs struggle as funding dries up.
Headquartered in Naarden, the Netherlands, and Munich, Germany, the European life sciences VC firm has just closed its Forbion Ventures Fund VI, which raised €750m from investors, alongside the Forbion Growth Opportunities Fund II, with €600m now on its books